Please ensure Javascript is enabled for purposes of website accessibility

Why XenoPort, Inc. Is Skyrocketing 56.6% Today

By Todd Campbell - May 23, 2016 at 2:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is being taken private by Arbor Pharmaceuticals.

Image source: XenoPort, Inc.

What: After  XenoPort, Inc. (NASDAQ: XNPT) announced that it has agreed to be acquired for $7.03 per share in cash, its shares are soaring 56.6% today.

So what: The board of directors has agreed to sell the company to Arbor Pharmaceuticals in a deal valued at $467 million. Arbor Pharmaceuticals is a privately held maker of drugs for the cardiovascular, hospital, and pediatric markets. It employs 500 sales people who promote 20 NDA or ANDA approved products.

The acquisition nets Arbor Pharmaceuticals' XenoPort's Horizant, a Food and Drug Administration-approved therapy for restless leg syndrome. In Q1, Horizant sales were $13.7 million, up 106% from the same quarter one year ago. Total tablet volume prescribed in the quarter grew 51% year over year. 

Now what: XenoPort has been making some progress with Horizant, but it was still losing money and burning through cash, so this deal makes sense.

Having said that, this is a cash deal, so there really isn't much reason for investors to consider buying XenoPort shares ahead of its expected close in the third quarter. There's a little arbitrage opportunity given the deal price, and another bidder could emerge. That, however, is a long shot since it sounds like management evaluated multiple offers and chose this one. Overall, it's probably best to focus on other investment ideas. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.